Dr. Hooman Noorchashm says FDA, Pfizer and Moderna must consider the danger COVID vaccines pose to the recently convalescent or asymptomatic carriers of SARS-CoV-2 — especially the elderly, frail or anyone with significant cardiovascular risk factors.
Noorchashm, M.D., Ph.D., is a physician-scientist and advocate for ethics, patient safety and women’s health. He specializes in cardiothoracic surgery and has taught and practiced medicine for nearly two decades.
“Dr. Noorchashm’s prognostications of harm in elderly individuals with cardiovascular disease coincides with the numerous reports of unexplained cardiovascular deaths following COVID-19 vaccination in Norway, Germany, the UK, Gibraltar and the U.S.,” said Lyn Redwood, RN, MSN, director and president emerita of Children’s Health Defense.
Redwood noted that J. Patrick Whelan, M.D., Ph.D., sent similar concerns to the FDA on Dec. 8, 2020.
Whelan raised even more worrisome questions, Redwood said, in that he cited research showing that in addition to the heart, ACE-2 receptors are also present in microvasculature of the brain, liver and kidney.
“Ignoring these valid and scientifically supported warnings from leading immunologists may result in hundreds of millions of people suffering potentially deadly injuries or permanent damage following vaccination,” Redwood said. “It will also further erode the dwindling confidence that our country has in our federal regulatory agencies to protect the health of all Americans.”
Redwood called on the FDA and Centers for Disease Control and Prevention to convene emergency meetings to review these concerns and issue new guidelines for vaccine administration that address these concerns.
Below is Noorchashm’s introduction to his letter, as published on Medium, followed by his letter to the FDA and Pfizer.
It is my sincere hope that this public letter might stimulate FDA, Pfizer and Moderna leaders to think critically and quickly about the immunological danger the COVID-19 vaccine might pose to the recently convalescent or asymptomatic carriers of SARS-CoV-2 — most especially to those who are elderly, frail or have significant cardiovascular risk factors.
I want to be clear that my warning here is based on a near definitive scientific Immunological prognostication. It is a “prognostication” in that I have put it forth in the absence of clear “evidence” of it being a material risk.This is because we are dealing with an evolving 11-month old national health emergency with many unknowns, and a vaccine that is only several weeks old — and was approved for massive scale use on the Emergency basis. And, in a setting where it is critical to quickly vaccinate as many citizens as possible to achieve herd immunity against SARS-CoV-2.